Recent chatter on X about Dynavax Technologies (DVAX) has been buzzing with excitement following the announcement of positive topline results from a Phase 1/2 trial for their shingles vaccine candidate, Z-1018. Many users have pointed out the vaccine's potential to rival established competitors, citing comparable immunity profiles and improved safety data as reasons for optimism. The stock's upward movement in premarket trading has further fueled discussions about its momentum.
Additionally, posts on X have highlighted analyst reiterations of strong price targets and outperform ratings for DVAX, with some suggesting that the latest trial data could mark a turning point after a challenging year-to-date performance. The focus remains on the upcoming trial phase for older adults, expected to start later in 2025, as a critical next step. Enthusiasm is tempered by cautious voices noting the competitive landscape in the biopharma sector.
Note: This discussion summary was generated from an AI condensation of post data.
Dynavax Technologies Insider Trading Activity
Dynavax Technologies insiders have traded $DVAX stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $DVAX stock by insiders over the last 6 months:
- TRACK BIOTECHNOLOGY MASTER FUND, LTD. DEEP has made 0 purchases and 2 sales selling 2,065,137 shares for an estimated $22,351,598.
- DAVID F NOVACK (President & COO) has made 0 purchases and 3 sales selling 56,784 shares for an estimated $801,865.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
Dynavax Technologies Hedge Fund Activity
We have seen 106 institutional investors add shares of Dynavax Technologies stock to their portfolio, and 192 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC removed 3,800,500 shares (-66.1%) from their portfolio in Q2 2025, for an estimated $37,700,960
- BLACKROCK, INC. removed 3,047,193 shares (-15.0%) from their portfolio in Q2 2025, for an estimated $30,228,154
- MILLENNIUM MANAGEMENT LLC added 1,386,541 shares (+612.1%) to their portfolio in Q2 2025, for an estimated $13,754,486
- INVESCO LTD. removed 1,221,651 shares (-55.3%) from their portfolio in Q2 2025, for an estimated $12,118,777
- EVERSEPT PARTNERS, LP added 1,197,189 shares (+inf%) to their portfolio in Q2 2025, for an estimated $11,876,114
- D. E. SHAW & CO., INC. removed 1,062,388 shares (-42.7%) from their portfolio in Q2 2025, for an estimated $10,538,888
- TWO SIGMA ADVISERS, LP added 1,019,800 shares (+110.7%) to their portfolio in Q2 2025, for an estimated $10,116,416
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Dynavax Technologies Analyst Ratings
Wall Street analysts have issued reports on $DVAX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- JMP Securities issued a "Market Outperform" rating on 08/08/2025
- Goldman Sachs issued a "Sell" rating on 04/17/2025
To track analyst ratings and price targets for Dynavax Technologies, check out Quiver Quantitative's $DVAX forecast page.
Dynavax Technologies Price Targets
Multiple analysts have issued price targets for $DVAX recently. We have seen 2 analysts offer price targets for $DVAX in the last 6 months, with a median target of $21.0.
Here are some recent targets:
- Roy Buchanan from JMP Securities set a target price of $32.0 on 08/22/2025
- Paul Choi from Goldman Sachs set a target price of $10.0 on 04/17/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
